Literature DB >> 2165348

Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria.

O Ijaola1, A O Falase.   

Abstract

The sera of eight endomyocardial fibrosis (EMF) subjects, 11 siblings of one of them and 16 normal children matched with the EMF patients for age, sex and socio-economic status from Ogunmakin and Shao/Oloru communities (eight each), situated in EMF-endemic and non-endemic areas of Nigeria respectively, were examined for the presence of antibodies against Coxsackie viruses B1-6, 16 arboviruses and Toxoplasma gondii. Sera from 36 other randomly selected normal children from Ogunmakin and 26 other randomly selected children from Shao/Oloru were also tested for the presence of antibodies against Toxoplasma gondii and the 16 arboviruses. None of the eight EMF subjects nor the 11 siblings of one of them had antibodies against any of the Coxsackie viruses B1-6 in their sera. Two of the 16 matched control subjects, one from each community, had positive antibodies, at equivocal titres against Coxsackie B1 (Ogunmakin) and B4 (Shao/Oloru). There was no significant difference in the distribution of antibody titres to the arboviruses between the EMF patients and matched controls. Normal children from the Shao/Oloru community had higher percentage antibody reactions and higher titres to the arboviruses compared with the children from Ogunmakin. All the eight EMF patients had high antibody titres against Toxoplasma gondii. Seven (87.5%) of the matched controls from Ogunmakin were sero-positive for Toxoplasma gondii compared with three (37.5%) of the matched controls from Shao/Oloru. Of the 36 normal children from Ogunmakin, 32 (88.9%) were sero-positive compared with 11 (42.3%) of the 26 normal children from Shao/Oloru. Four (36.4%) of the 11 siblings of one of the EMF patients had weak sero-positivity. It is therefore concluded that further studies are needed to clarify the role, if any, of Toxoplasma gondii in EMF.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165348

Source DB:  PubMed          Journal:  Afr J Med Med Sci        ISSN: 0309-3913


  7 in total

1.  Neovascularity related to mural thrombus in endomyocardial fibrosis.

Authors:  M Meuwissen; G A Somsen; J J Piek
Journal:  Int J Card Imaging       Date:  1999-06

2.  Endomyocardial fibrosis: pathological and molecular findings of surgically resected ventricular endomyocardium.

Authors:  Silvia D'Andretta Iglezias; Luiz Alberto Benvenuti; Fiorella Calabrese; Vera Maria Cury Salemi; Ana Maria Gonçalves Silva; Elisa Carturan; Sergio Almeida de Oliveira; Gaetano Thiene; Thales De Brito
Journal:  Virchows Arch       Date:  2008-09-02       Impact factor: 4.064

3.  Severe Left Ventricular Endomyocardial Fibrosis Presenting as Biventricular Failure in a Young Adult: A Case Report.

Authors:  Harpreet Singh Sandhu; Sampathkumar Mahadevappa Mahendrakar; Rajebali Ramzanali Pethani; Azizullah Hafizullah Khan; Yunus Shafi Loya
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 4.  Endomyocardial Fibrosis: an Update After 70 Years.

Authors:  Ana Olga Mocumbi; J Russell Stothard; Paulo Correia-de-Sá; Magdi Yacoub
Journal:  Curr Cardiol Rep       Date:  2019-11-22       Impact factor: 2.931

Review 5.  Endomyocardial fibrosis: still a mystery after 60 years.

Authors:  Gene Bukhman; John Ziegler; Eldryd Parry
Journal:  PLoS Negl Trop Dis       Date:  2008-02-27

Review 6.  Emerging Viral Infections, Hypertension, and Cardiovascular Disease in Sub-Saharan Africa: A Narrative Review.

Authors:  Lily D Yan; Sarah S Matuja; Kevin J Pain; Margaret L McNairy; Anthony O Etyang; Robert N Peck
Journal:  Hypertension       Date:  2022-03-11       Impact factor: 9.897

Review 7.  Endomyocardial fibrosis: A form of endemic restrictive cardiomyopathy.

Authors:  Ana Olga Mocumbi
Journal:  Glob Cardiol Sci Pract       Date:  2012-07-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.